For their recent publication
Britta Gerlach, PhD

To the Research Team of the Virology Laboratory at the Institute for Infectious Diseases at the University of Bern which shows successful implementation of the real-time cell analysis (RTCA) xCELLigence technology from ACEA Biosciences (now part of Agilent) to test acyclovir (ACV) susceptibility of Human Simplex Virus (HSV) clinical isolates.

OLS is happy to see that this method might help to adjust appropriate antiviral treatment for patients with refractory HSV infections and helping by getting faster and more efficient time to results!


  • Cell viability tracing by impedance measurement, no additional dyes or chemicals.
  • Dynamic tracing of cell growth and CPE over the whole experimental period.
  • Less labor-intensive phenotypic resistance testing.
  • Efficient and reliable susceptibility testing by xCELLigence RTCA system


The Author’s Conclusion:

Compared with other phenotypic methods, RTCA analysis requires less manipulation, reduces the workload and the turnaround time, and appears to be an objective and reliable method to test ACV susceptibility.

Publication:; J Clin Virol . 2020 Feb 19;125:104303

xCELLigence RTCA technology

Learn more about the xCELLigence RTCA technology

Learn more

xCELLigence RTCA eSight technology

Learn more about the xCELLigence RTCA eSight technology

Learn more

Subscribe for our newsletter



By submitting my data and sending the registration, I agree to receive the newsletter ordered here by email. My data will not be disclosed to third parties. I can revoke this consent at any time. More detailed information in the Privacy Policy section

Your Partner in Cell Research
Imprint | Privacy Policy | Terms and Conditions